Eli Lilly (LLY): FY24 Q4 earnings call, Feb 6, 2025
No Kalshi or Polymarket word markets were listed for Eli Lilly’s Feb 6, 2025 earnings call (FY24 Q4). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
22 matches for “Mounjaro”; 5 quoted, at least 25 words apart.
…growing by more than $3.1 billion, led by a strong uptake of Mounjaro and Zepbound. Q4 also saw a solid performance across oncology, immunology and…
…As Dave mentioned, our revenue grew 45% in Q4, primarily driven by Mounjaro and Zepbound. Performance of our non-incretin portfolio was also strong as revenue…
…ongoing and future launches. This includes U.S. direct-to-consumer advertising on Zepbound and Mounjaro and U.S. launch activities for Kisunla and Ebglyss. We also increased our…
…40% in Q4, driven by robust volume growth of 45%. Zepbound and Mounjaro were again the largest growth contributors, partially offset by declines in Trulicity.…
…in constant currency. We continue to be pleased with the uptake of Mounjaro and have now launched in all major European markets. In addition to…
Agents: this page as TSV at /api/v1/appearances/eli-lilly:2025-02-06:earnings_call · words: /api/v1/brief?appearance=eli-lilly:2025-02-06:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP